GTH - Genetron Health Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

Genetron Holdings (GTH) and Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical (SBHMY) and a leading liver drug franchise with a major presence in liver disease hospitals in China entered in an exclusive strategic partnership agreement for HCCscreen, the former’s blood-based early detection of hepatocellular carcinoma in individuals who are designated to be at high-risk due to chronic HBV infection and/or liver cirrhosis in China.The partnership will focus the hospital market in China, on combatting liver disease, and is Genetron Health's third commercialization initiative of HCCscreen in the country.Under the agreement, the companies will work together exclusively to co-market and co-promote HCCscreen in the hospital market, covering designated territories in China and intends to target high-risk individuals for HCC, which include HBV-positive carriers, as well as other liver disease patients.Pursuant to the transaction, Genetron Health will pay CTTQ a promotional fee based on a percentage of revenues generated from the collaboration.As a result of the agreement,

For further details see:

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China